不同生物标志物在静脉血栓栓塞症中应用价值的研究进展  

Application Value of Different Biomarkers in Venous Thromboembolism

作　　者：张鹏[1] 刘金波[1,2] 王宏宇 ZHANG Peng;LIU Jinbo;WANG Hongyu(Department of Vascular Medicine,Peking University Shougang Hospital,Beijing 100144,China;Vascular Health Research Center of Peking University Health Science Center,Beijing 100144,China;Key Laboratory of Molecular Cardiovascular Sciences(Peking University),Ministry of Education,Beijing 100144,China)

机构地区：[1]北京大学首钢医院血管医学中心,北京100144 [2]北京大学医学部血管健康研究中心,北京100144 [3]北京大学分子心血管学教育部重点实验室,北京100144

出　　处：《心血管病学进展》2021年第11期978-981,共4页Advances in Cardiovascular Diseases

基　　金：教育部科技发展中心产学研创新基金“智融兴教”基金(2018A02004);国家重点研发计划(2017YFC0113005,2017YFC0113003);首颐医疗科技发展基金2019年度临床重点项目(2019-Yuan-LC-01);2020年首都卫生发展科研专项(首发2020-2-6042)。

摘　　要：肺血栓栓塞症和下肢深静脉血栓形成统称为静脉血栓栓塞症,在全世界范围内二者的发病率很高,肺血栓栓塞症亦是一种病死率很高的疾病。目前在指导临床应用中生物标志物的作用越来越受到重视,如何合理选用生物标志物并正确分析其临床应用价值的侧重点,尚缺乏系统性的认识。现对不同生物标志物在静脉血栓栓塞症中的应用价值做一综述。Pulmonary thromboembolism and deep vein thrombosis of the lower extremities are collectively referred to as venous thromboembolism,both have a high incidence worldwide,and pulmonary thromboembolism is also a disease with a high mortality rate.At present,more and more attention is paid to the role of biomarkers in guiding clinical applications.There is still a lack of systematic understanding of how to rationally select biomarkers and correctly analyze their clinical application value.The application value of different biomarkers in venous thromboembolism is reviewed in this paper.

关 键 词：生物标志物 静脉血栓栓塞症 应用价值 

分 类 号：R543.6[医药卫生—心血管疾病]